Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response Study of OPC-12759 in Dry Eye
NCT00234078Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2005
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rebamipide in dry eye syndrome (DED) (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Fluorescein Corneal Staining Score at 12 weeks and Primary Ocular Discomfort Score at 12 weeks. Started Jan 2005; status: completed.
02
Drugs
rebamipide
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT00234078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234078.